Department of Clinical Biochemistry, University Hospital of South Manchester, Southmoor Road, Wythenshawe, Manchester M23 9LT, UK.
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 1;878(7-8):695-9. doi: 10.1016/j.jchromb.2010.01.010. Epub 2010 Jan 18.
In patients with carcinoid disease, urinary concentration of the serotonin metabolite 5-hydroxyindole acetic acid (5-HIAA) is currently used to monitor disease progression or response to treatment as it is the metabolic end-product resulting from free and stored serotonin turnover. However, due to the undignified, cumbersome and error-prone nature of 24-h urine collections, there is constant pressure to replace them. It has been demonstrated using high performance liquid chromatography (HPLC) with fluorescence detection technology that plasma can achieve this, with the added advantage that it can be used for diagnostic purposes also. Here we describe a much simpler method using liquid chromatography-tandem mass spectrometry (LC-MS/MS) that is twice as fast as a HPLC method currently in routine use. The sample preparation protocol requires 50 micorL of plasma and a simple protein precipitation step facilitated by acetonitrile. Chromatography was performed on a Phenomenex C18 Security Guard column coupled to a SIELC Primesep B reversed-phase, anion-exchange dual chemistry column and methanolic mobile phase gradient elution. Eluant was directly connected to a Waters Quattro Premier XE tandem mass spectrometer operating in positive ion mode. We detected multiple reaction monitoring transitions m/z 191.9>145.6 and 193.9>147.6 for 5-HIAA and d2-5-HIAA respectively, which co-eluted at 2.1 min. Ion suppression was negligible, recovery from spiked plasma was 103% (range 97-113%) and the method showed good linearity to 10,000 nmol/L (r(2)=0.999). Within-batch and between-batch imprecision was <10% and bias <15% at 3 concentrations, the limit of detection was 5 nmol/L and lower limit of quantitation 15 nmol/L. No interference was observed with l-tryptophan or 5-hydroxytryptamine. Comparison of LC-MS/MS and HPLC showed good agreement between the two methods but this LC-MS/MS assay displays several advantages; it requires 10-fold less sample, has a simpler extraction procedure and extended linearity, thus increasing laboratory throughput, lowering reagent costs and removing the need to dilute samples in patients with established carcinoid disease being monitored for therapeutic efficacy.
在类癌疾病患者中,尿 5-羟吲哚乙酸(5-HIAA)浓度目前用于监测疾病进展或治疗反应,因为它是源自游离和储存的 5-羟色胺转化的代谢终产物。然而,由于 24 小时尿液采集的方式不卫生、繁琐且容易出错,因此一直存在取代它的压力。使用高效液相色谱(HPLC)和荧光检测技术已经证明,血浆可以实现这一点,而且还有一个额外的优势,即它也可用于诊断目的。在这里,我们描述了一种使用液相色谱-串联质谱(LC-MS/MS)的简单得多的方法,该方法比目前常规使用的 HPLC 方法快两倍。该样品制备方案需要 50 微升血浆,并且通过乙腈进行简单的蛋白质沉淀步骤。色谱在 Phenomenex C18 Security Guard 柱上进行,与 SIELC Primesep B 反相、阴离子交换双化学柱相连,采用甲醇流动相梯度洗脱。洗脱液直接连接到 Waters Quattro Premier XE 串联质谱仪,以正离子模式运行。我们检测到 5-HIAA 和 d2-5-HIAA 的多重反应监测转换 m/z 191.9>145.6 和 193.9>147.6,它们在 2.1 分钟时共洗脱。离子抑制可忽略不计,从加标血浆中的回收率为 103%(范围 97-113%),该方法在 10,000nmol/L 时表现出良好的线性(r(2)=0.999)。在 3 个浓度下,批内和批间精密度<10%,偏差<15%,检测限为 5nmol/L,定量下限为 15nmol/L。L-色氨酸或 5-羟色胺没有观察到干扰。LC-MS/MS 与 HPLC 的比较表明两种方法之间具有良好的一致性,但这种 LC-MS/MS 测定具有几个优点;它需要的样品少 10 倍,提取程序更简单,线性扩展,从而提高了实验室通量,降低了试剂成本,并消除了在接受治疗效果监测的已确诊类癌疾病患者中稀释样品的需要。